Blog Posts

James Davis: Dexamethasone for CRS with teclistamab in R/R Multiple Myeloma

James Davis/X

Mar 5, 2025, 12:14

James Davis: Dexamethasone for CRS with teclistamab in R/R Multiple Myeloma

James Davis, Assistant professor and malignant hematology pharmacist at MUSC Hollings Cancer Center, shared an article he and his colleagues authored on X:

“Hot off the press!

Dexamethasone for CRS with teclistamab. You don’t need toci for grade 1 CRS! great team work.”

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma

Authors: James Davis et al.

multiple myeloma

Rahul Banerjee, Assistant professor at Fred Hutchinson Cancer Center at the University of Washington, reshared the post on X, adding:

“Congrats James Davis et al for great Blood Cancer Journal work!

Consider prescribing “pocket dex” for patients following Multiple Myeloma bsAbs. 10mg for Gr1 CRS after ing with team. Easier for pts, easier for centers, works well, and much cheaper than toci!”

Charlotte B. Wagner Christopher Cahoon Donald C. Moore Grace Elsey Hailey Hill Jack Khouri James A. Davis James Davis Jessica McElwee Jordan Snyder Joslyn Rudoni Katelynn Granger Kelley Julian Kimberly M. Green Mikhaila Rice Shebli Atrash Victoria R. Nachar Zahra Mahmoudjafari

Padraic O’Malley: Meet the Experts of VIRO 2025

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

FDA Breakthrough Therapy Designation for Iza-bren: Advancing Treatment for EGFR-Mutant NSCLC

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen